Welcome to XLH Research. The goal of this webpage is to provide an update on current endeavours to develop new cures (or to optimize current ones) for XLH (X-Linked Hypophosphatemia)
Copyright (C) 2005 by Pol Harvengt.
Recombinant Phex protein
Enobia Pharma is developping an ERT (Enzyme Replacement Therapy) using a recombinant soluble form of Phex, the defective protein of XLH patients.
Kansas City's Children of Mercy Hospital is currently leading a clinical trial to investigate about the potential benefits of the calcimimetic Cinacalcet on children with XLH.
ED-71 from Chugai Pharma is in Phase III trial for osteoporosis in US. Preclinical data inidicates that the compound could be of interest also for XLH.
